Hengrui Pharmaceuticals’ approval of Heng Qin® — also known as Perfluorohexyloctane Eye Drops — represents a significant advancement in treating dry eye disease associated with Meibomian gland dysfunction. This breakthrough innovation addresses a previously unmet medical need in ophthalmology.

As the first drug specifically approved for Meibomian gland dysfunction-related dry eye disease in China, this water-free, preservative-free formulation utilizes Novaliq’s proprietary EyeSol® technology to stabilize the tear film by supplementing lipid layers and reducing evaporation. Clinical trials of Heng Qin® demonstrated rapid symptom improvement within two weeks and sustained efficacy through eight weeks, with favorable safety comparable to saline controls. The approval fills a critical gap in China’s ocular therapeutics market, where 21-30% of the population suffers from dry eye disease.

Image Credit: Hengrui Pharmaceuticals